Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-15 am EDT			5-day change	1st Jan Change
4,823 ^JPY	+0.52%		-2.09%	-9.72%

May. 14	Japan's Nikkei drifts sideways as more earnings, US CPI awaited	RE
May. 01	Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	MT

Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending December 2023

April 27, 2023 at 04:00 am EDT

Chugai Pharmaceutical Co., Ltd. expects dividend of ¥40 per share for the second quarter of fiscal year ending December 2023.

Latest news about Chugai Pharmaceutical Co., Ltd

Japan's Nikkei drifts sideways as more earnings, US CPI awaited	May. 13	RE
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	May. 01	MT
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	Apr. 25	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	Apr. 24	MT
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending December 31, 2024; Provides Dividend Guidance for the Year Ending December 31, 2024	Apr. 24	CI
Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	Feb. 01
Chugai Pharmaceutical’s Profit Down 13% in 2023	Feb. 01	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024	Feb. 01	CI
From scandal to delisting: Toshiba's long-running crisis	Dec. 19	RE
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy	Dec. 14	MT
Transcript : Chugai Pharmaceutical Co., Ltd. - Pre Recorded Special Call	Nov. 27
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
Chugai Pharmaceutical’s Attributable Profit down 13.9% in Fiscal due to One-Off Lump-Sum Settlement;Shares Shed over 2.6%	23-10-24	MT
Chugai Parent Roche Settles US Lawsuit Against Biogen Over Alleged Biosimilar Infringement	23-10-24	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023	23-10-24	CI
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2023	23-10-24	CI
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar	23-10-23	MT

Chart Chugai Pharmaceutical Co., Ltd

Duration

Period

More charts

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

2024-06-26 - Ex-dividend day for dividende intermédiaire

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Chugai Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,798 JPY

Average target price

6,021 JPY

Spread / Average Target

+25.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHUGAI PHARMACEUTICAL CO., LTD	-9.72%	50.47B
ELI LILLY AND COMPANY	+31.06%	688B
NOVO NORDISK A/S	+30.35%	588B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	326B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	239B
NOVARTIS AG	+10.16%	210B
ROCHE HOLDING AG	-8.14%	200B
AMGEN INC.	+8.12%	167B

Other Pharmaceuticals